Drug Trial Radar · NCT05458011
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
365
Actual
Start
Sep 30, 2022
Primary completion
Jan 31, 2024
Study completion Jun 13, 2024
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Jul 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine. Secondary Objectives: * To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections. * To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.
Conditions
- Migraine
Interventions
FremanezumabDrug
Pharmaceutical form: solution for injection Route of administration: subcutaneous injection
PlaceboDrug
Pharmaceutical form: solution for injection Route of administration: subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind (DB) Period: Mean Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of FremanezumabTime frame: Baseline (Day -28 to Day -1), up to Week 12
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Teva Investigational Site 88028
Baotou Shi, China
Teva Investigational Site 88004
Beijing, China
Teva Investigational Site 88001
Beijing, China
Teva Investigational Site 88008
Changchun, China
Teva Investigational Site 88009
Changchun, China
Teva Investigational Site 88022
Changsha Shi, China
Teva Investigational Site 88030
Changsha Shi, China
Teva Investigational Site 88003
Chengdu, China
Teva Investigational Site 88029
Chongqing, China
Teva Investigational Site 88019
Fuzhou, China
Teva Investigational Site 88020
Guangzhou, China
Teva Investigational Site 88013
Guiyang, China
Teva Investigational Site 88026
Harbin, China
Teva Investigational Site 88010
Lianyungang, China
Teva Investigational Site 88005
Luoyang, China
Teva Investigational Site 88033
Rizhao, China
Teva Investigational Site 88021
Shanghaishi, China
Teva Investigational Site 88025
Shanghaishi, China
Teva Investigational Site 88016
Shenyang, China
Teva Investigational Site 88011
Shijiazhuang, China
Teva Investigational Site 88015
Suzhou, China
Teva Investigational Site 88024
Tianjin, China
Teva Investigational Site 88023
Tianjin, China
Teva Investigational Site 88017
Wenzhou, China
Teva Investigational Site 88012
Wuhan, China
Teva Investigational Site 88006
Wuhan, China
Teva Investigational Site 88032
Xining, China
Teva Investigational Site 88031
Zhanjiang, China
Teva Investigational Site 88034
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.